Pages that link to "Item:Q2846433"
From MaRDI portal
The following pages link to Design and estimation for evaluating principal surrogate markers in vaccine trials (Q2846433):
Displaying 12 items.
- Design and analysis of vaccine studies (Q1040907) (← links)
- Design of vaccine trials during outbreaks with and without a delayed vaccination comparator (Q1647615) (← links)
- Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy (Q2001894) (← links)
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption (Q2170431) (← links)
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling (Q3119801) (← links)
- Estimating correlations between vaccine clinical trial outcomes (Q5044656) (← links)
- A unified evaluation of differential vaccine efficacy (Q6047741) (← links)
- Efficient nonparametric inference on the effects of stochastic interventions under two‐phase sampling, with applications to vaccine efficacy trials (Q6079255) (← links)
- Semiparametric pseudo-score and pseudo-likelihood for evaluating correlate of protection in vaccine trials (Q6626858) (← links)
- MEBoost: variable selection in the presence of measurement error (Q6627157) (← links)
- Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm (Q6628202) (← links)
- Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials (Q6636037) (← links)
